CIK 0000882796 · Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 621413174
- Phone
- 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-12-15 | Gayer Charles K Chief Commercial Officer | Sale | −6,100 | $10.90 | $66K | 211,610 |
| 2022-12-15 | Jones Michael L Exec. Director, Finance - PAO | Sale | −445 | $10.90 | $5K | 10,753 |
| 2022-12-15 | Barnes Alane P Chief Legal Officer | Sale | −4,175 | $10.88 | $45K | 198,770 |
| 2022-12-02 | Stonehouse Jon P President & CEO | Option exercise | +82,656 | $1.42 | $117K | 984,486 |
| 2022-12-02 | Stonehouse Jon P President & CEO | Sale | −82,656 | $12.80 | $1.1M | 901,830 |
| 2022-12-02 | Stonehouse Jon P President & CEO | Option exercise · Emp. Stock Option (Right to Buy) | −82,656 | 0 | ||
| 2022-12-01 | Jones Michael L Exec. Director, Finance - PAO | Option exercise | +8,600 | $1.42 | $12K | 19,798 |
| 2022-12-01 | Jones Michael L Exec. Director, Finance - PAO | Sale | −8,600 | $13.01 | $112K | 11,198 |
| 2022-12-01 | Jones Michael L Exec. Director, Finance - PAO | Option exercise · Emp. Stock Option (Right to Buy) | −8,600 | 0 | ||
| 2022-12-01 | Stonehouse Jon P President & CEO | Option exercise | +214,917 | $1.42 | $305K | 1,116,747 |
| 2022-12-01 | Stonehouse Jon P President & CEO | Sale | −214,917 | $13.00 | $2.8M | 901,830 |
| 2022-12-01 | Stonehouse Jon P President & CEO | Option exercise · Emp. Stock Option (Right to Buy) | −214,917 | 82,656 | ||
| 2022-11-30 | HEGGIE THERESA Director | Grant or award | +421 | $13.36 | $6K | 31,054 |
| 2022-11-30 | MILANO VINCENT Director | Grant or award | +421 | $13.36 | $6K | 31,191 |
| 2022-11-30 | LEVIN ALAN G Director | Grant or award | +842 | $13.36 | $11K | 17,714 |
| 2022-11-30 | INGRAM ROBERT ALEXANDER Director | Grant or award | +1,497 | $13.36 | $20K | 97,939 |
| 2022-11-14 | Babu Yarlagadda S Chief Discovery Officer | Option exercise | +50,000 | $1.42 | $71K | 280,056 |
| 2022-11-14 | Babu Yarlagadda S Chief Discovery Officer | Option exercise | +50,000 | $1.42 | $71K | 330,056 |
| 2022-11-14 | Babu Yarlagadda S Chief Discovery Officer | Sale | −31,515 | $13.88 | $437K | 298,541 |
| 2022-11-14 | Babu Yarlagadda S Chief Discovery Officer | Option exercise · Emp. Stock Option (Right to Buy) | −50,000 | 0 |
Page 14 of 18 · 357 trades